- Luvelta demonstrated encouraging preliminary anti-tumor activity (29% response rate) in late-stage patients with recurrent/relapsed endometrial cancer with tumor proportion score (TPS) >25% FolRα expression –
- Safety profile was consistent with prior data in patients with platinum-resistant ovarian cancer -
Initial data from the Phase 1 dose-expansion study of luvelta were presented by Bhavana Pothurri, M.D., Professor,
Advanced endometrial cancer is the only gynecologic malignancy with increasing incidence and mortality in both the US and
“We are pleased to have the opportunity to present these encouraging early data at ESMO this year,” said
FolRα is a validated anti-tumor target in ovarian cancer that is overexpressed in endometrial cancer compared with normal tissue5. As presented in
ESMO Presentation Highlights:
- 17 patients were enrolled and initial data were presented on 16 patients with at least one post baseline scan
- Luvelta demonstrated encouraging preliminary anti-tumor activity in patients with FolRα-expressing endometrial cancer
- In patients with TPS >25% FolRα expression (n=7):
- Confirmed partial response (PR) was seen in 29% (2/7)
- Disease Control Rate (DCR) was 86% (6/7)
- In patients with TPS ≥1% FolRα expression (n=16):
- Confirmed PR was seen in 19% (3/16)
- DCR was 69% (11/16)
- In patients with TPS >25% FolRα expression (n=7):
- Consistent with previous reported luvelta safety results, the most common adverse event was neutropenia; no new safety signals were observed
The Presentation will be accessible through the News & Events page of the Investor Relations section of the company’s website at www.sutrobio.com.
*1: Siegel RL, et al. CA Cancer J Clin. 2023;73(1):17–48.
*2: European Cancer Information System (ECIS). https://ecis.jrc.ec.europa.eu. Accessed
*3: American Cancer Society Cancer Statistics 2023. https://www.cancer.org. Accessed
*4: Makker V, et al. N Engl J Med. 2022;386(5):437–448.
*5: Despierre E, et al. Gynecol Oncol. 2013;130:192–199.
About Sutro
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated preclinical and clinical development activities, timing of announcements of clinical results, trial initiation, and regulatory filings, potential benefits of luvelta and the Company’s other product candidates and platform, potential future milestone and royalty payments, and potential market opportunities for luvelta and the Company’s other product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the Company’s ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates and the Company’s ability to successfully leverage Fast Track designation, the market size for the Company’s product candidates to be smaller than anticipated, the impact of the COVID-19 pandemic on the Company’s business, clinical trial sites, supply chain and manufacturing facilities, the Company’s ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, the Company’s ability to fund development activities and achieve development goals, the Company’s ability to protect intellectual property, the value of the Company’s holdings of Vaxcyte common stock, and the Company’s commercial collaborations with third parties and other risks and uncertainties described under the heading “Risk Factors” in documents the Company files from time to time with the
Contact
(650) 823-7681
ewhite@sutrobio.com
Source:
2023 GlobeNewswire, Inc., source